Your browser doesn't support javascript.
loading
Availability of anticancer biosimilars in 40 countries.
Huang, Hui-Yao; Wu, Da-Wei; Ma, Fei; Liu, Zhi-Lei; Shi, Ju-Fang; Chen, Xia; Wang, Shu-Hang; Fang, Hong; Bai, Ying; Yu, Yue; Fang, Yuan; Sun, Chao; Fan, Qi; Wu, Ying; Fan, Rui-Hua; Zhou, Cai-Yun; He, Bao-Xia; Dai, Min; Li, Ning; Xu, Bing-He; Sun, Yan; He, Jie.
Affiliation
  • Huang HY; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Wu DW; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Ma F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Liu ZL; Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
  • Shi JF; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Chen X; Clinical Trial Center, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Wang SH; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Fang H; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Bai Y; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Yu Y; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Fang Y; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Sun C; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Fan Q; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Wu Y; Pfizer Investment, Shanghai, China.
  • Fan RH; Phase I Clinical Trial Center, Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huaian, China.
  • Zhou CY; Huludao Cancer Quality Control Center, Huludao Central Hospital, China.
  • He BX; Clinical Trials Institute, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Dai M; Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Li N; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: lining@cicams.ac.cn.
  • Xu BH; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Sun Y; Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • He J; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lancet Oncol ; 21(2): 197-201, 2020 02.
Article in En | MEDLINE | ID: mdl-32007192
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Natural Killer T-Cells / Biosimilar Pharmaceuticals / Lymphoma Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2020 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Natural Killer T-Cells / Biosimilar Pharmaceuticals / Lymphoma Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2020 Document type: Article Affiliation country: China